1 / 39

Treatment of APL: view of guidelines 2. Recent studies for optimization

Breakthroughs in the treatment of acute promyelocytic leukemia: curable disease with retinoic and arsenic Jiong HU Shanghai Institute of Hematology, Department of Hematology, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine. Treatment of APL: view of guidelines

onan
Download Presentation

Treatment of APL: view of guidelines 2. Recent studies for optimization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breakthroughs in the treatment of acute promyelocytic leukemia: curable disease with retinoic and arsenic Jiong HU Shanghai Institute of Hematology, Department of Hematology, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine

  2. Treatment of APL: view of guidelines 2. Recent studies for optimization - Role of arsenic as upfront treatment - ATRA+arsenic with or without chemotherapy - Oral formula of arsenic 3. Perspectives

  3. Treatment of APL: view of guidelines • ELN guideline / NCCN guideline / Consensus of CSH: • Induction: simultaneous administration of ATRA and anthracycline-based chemotherapy as standard • - Relapse: Arsenic as the best treatment option Blood 2009;113:1875 Chin J Hematol 2010;31:69

  4. Treatment of APL: view of guidelines Tallman M, Blood 2009;114(25):5126

  5. RFS outcome Low risk: WBC <10,000 and platelets >40,000 Intermediate risk : WBC < 10,000 and platelets < 40,000 High risk: WBC > 10,000 Risk Stratification Sanz MA, Blood. 2000;96:1247

  6. Treatment of APL: view of guidelines 2. Recent studies for optimization - Role of arsenic as upfront treatment - ATRA+arsenic with or without chemotherapy - Oral formula of arsenic 3. Summary

  7. Optimization: role of upfront arsenic • Rationale: • Clinical evidence: • efficacy in relapse patients: high remission rate with sizable proportion of long-term survival • efficacy in newly-diagnosed patients as single agent: long-term survival

  8. Outcome from Shanghai Institute of Hematology • Arsenic as Induction and maintenance therapy: • - Induction: • ATRA 25mg/m2/d, given orally，until CR • As2O3 0.16mg/kg/d，iv drip until CR • chemotherapy added to control hyperleukocytosis • Consolidation therapy: DA, ID-Ara-C, HA • Maintenance: 3 months of sequential use of RA/Arsenic/chemo • ATRA:25mg/m2/d,given orally for 15-30 days • As2O3: 0.16mg/m2/d for 28 days • 6-mercaptopurine (6-MP): 100mg/d for 30 days • or Methotrexate 15mg, once a week, for 4 weeks

  9. n=85, 91.7±3.0% n=85, 89.2±3.4% Follow-up data – 85 patients with ATRA+ATO: Survival at 70 months Overall survival Event-free survival Hu J, PNAS 2009;106:3342

  10. n=80, 94.82.5% n=80, 97.41.8% Follow-up data – 80 patients with ATRA+ATO entered CR: Survival at 70 months Overall survival Relapse-free survival Hu J, PNAS 2009;106:3342

  11. Arsenic concentration 2 years after the treatment Hu J, PNAS 2009;106:3342

  12. North American Leukemia Intergroup Study C9710 (NCT00003934) Arsenic as consolidation Powell BL,Blood First Edition Paper, DOI 10.1182/blood-2010-02-269621

  13. North American Leukemia Intergroup Study C9710 (NCT00003934) Powell BL,Blood First Edition Paper, DOI 10.1182/blood-2010-02-269621

  14. North American Leukemia Intergroup Study C9710 (NCT00003934) Powell BL,Blood First Edition Paper, DOI 10.1182/blood-2010-02-269621

  15. MDACC Study • Arsenic as induction and post-remission therapy - ATRA + ATO  gemtuzumab ozogamicin (GO) (high-risk disease: WBC  10 x 109/L) - 75 / 82 achieved CR (92%), 7 death - Median follow-up: 99 weeks (2 - 282) - 3 relapse (39, 52, 53 weeks) - 3 death (14, 21, 71 weeks; all due to secondary malignancies) - estimated 3-year OS: 85% Ravandi F, J Clin Oncol,2009;27:504

  16. Treatment of APL: view of guidelines 2. Recent studies for optimization - Role of arsenic as upfront treatment - ATRA+arsenic combination with or without chemotherapy - Oral formula of arsenic 3. Summary

  17. ATRA+arsenic without chemotherapy • “appealing concept” of curative regimen by target therapy only in leukemia • avoid the potential toxicity of chemotherapy

  18. ATRA+arsenic without chemotherapy • Rationales: • ATRA and arsenic synergy in targeting APL • targeting PML-RARA • upregulation of expression of AQP9 and arsenic uptake • animal data • potentially targeting FLT-3 • - Arsenic targeting LSC/LIC

  19. Importance of ATRA/ATO vs. ATRA/chemo? Synergy of ATO and ATRA eradicate leukemia initiating cells (LIC) • ATRA and ATO directly target PML/RAR by RARA moiety of the fusion and PML part • ATRA-ATO synergizes for PML/RAR induced differentiation and apoptosis which has a major role in debulking of the leukemia cells • degradation PML-RAR rapidly clears leukemia initiating cells (LIC), resulting in APL eradication in murine APL models • Bortezomib blocked PML-RAR degradation and reversed the curative effect of the ATRA + ATO Nasr R, Nat Med. 2008;14:1333 and Clin Cancer Res 2009 Oct 6.

  20. Synergy of ATO and ATRA eradicate leukemia initiating cells (LIC) Scott Kogan, Cancer Cell 2009;15:7

  21. ATRA/ATO reduce significantly use of chemotherapy: Australian APML4 study 3 cycles of ATRA + ATO in induction/consolidation; 1 cycle of idarubicin in induction Iland HJ, Blood. 2012;120(8):1570-1580

  22. ATRA/ATO reduce significantly use of chemotherapy: Australian APML4 study 2-year relapse-free survival 97.5%; failure-free survival 88.1%, and overall survival 93.2%. Iland HJ, Blood. 2012;120(8):1570-1580

  23. ATRA/ATO reduce significantly use of chemotherapy: Australian APML4 study Superior to APML3 trial: ATRA+Ida in induction; Ida/Ara-c+VP-16 consolidaiton; ATRA+MTX-6-MP maintenance Iland HJ, Blood. 2012;120(8):1570-1580

  24. ATRA + ATO vs AIDA in newly-diagnosed non high-risk APL: Gimema-SAL-AMLSG • Phase III, randomized study • Treatment: • - ATO 0.15/kg + ATRA 45mg/m2 induction --- ATO 5 days/week (4 weeks on/off) 4 courses + ATRA (2 weeks on/off) 7 courses • - AIDA: ATRA+Ida induction --- 3 cycles of anthracycline + ATRA consolidation --- low dose CHT + ATRA maintenance • Primary endpoint: 2-year EFS • Secondary endpoints: OS, DFS, CIR rates, molecular response and toxicity profile      ASH 2012, Plenary Scientific Session

  25. ATRA + ATO vs AIDA in newly-diagnosed non high-risk APL: Gimema-SAL-AMLSG • Patients: • 162 enrolled 154 evaluable • median age 45.3(18.7-70.2); median WBC 1.50 x 109/L • risk: 61.8% intermediate and 38.2% low-risk • median FU: 31 months (range 0.07-50.4) ASH 2012, Plenary Scientific Session

  26. ATRA + ATO vs AIDA in newly-diagnosed non high-risk APL: Gimema-SAL-AMLSG For newly diagnosed non-high-risk APL, the front-line chemo-free ATO+ATRA therapy is at least not inferior to AIDA in terms of 2 year EFS. ASH 2012, Plenary Scientific Session

  27. ATRA/ATO with or without chemotherapy in newly-diagnosed APL in China • Chinese 863 Key program study • Multiple-center randomized study • Newly-diagnosed APL • Risk stratification: low-risk vs. int/high-risk • - Low-risk: ATO replacing chemotherapy • - Int or high- risk: ATO reduce chemotherapy (Ara-C) • 20 clinical centers enrolled from Aug 2012 to Aug 2015

  28. ATRA/ATO with or without chemotherapy in newly-diagnosed APL in China

  29. Treatment of APL: view of guidelines 2. Recent studies for optimization - Role of arsenic as upfront treatment - ATRA+arsenic without chemotherapy - Oral formula of arsenic 3. Summary

  30. Oral Arsenic trioxide: Hong Kong • Retrospective analysis of 76 APL in 1st CR • Treatment: • - Induction/consolidation: daunorubicin and Ara-C • - Maintenance: oral arsenic trioxide based regimen • oral ATO (10 mg/day); • oral ATO + ATRA(45mg/m2); • oral ATO+ATRA+ascorbic acid (1000 mg/day) • given 2 weeks every 2 months for 2 years Au WY et al. Blood. 2011;118(25):6535-6543

  31. Oral Arsenic trioxide: Hong Kong • Toxicities observed in maintenance: • - headache, dyspepsia, reversible liver function abnormality • and herpes zoster reactivation • - QT prolongation not significant • Median follow-up of 24 months (range, 1-115 months): • - relapse only in 8 patients • - 3-year LFS and OS: 87.7% and 90.6% Au WY et al. Blood. 2011;118(25):6535-6543

  32. Oral Arsenic trioxide: Hong Kong Au WY et al. Blood. 2011;118(25):6535-6543

  33. Oral Realgar-Indigo Naturalis Formula (As4S4) vs. ATO: Multi-Center Randomized Trial APL07 HA As2O3 / ATRA ATRA +As2O3 Newly-diagnosed APL MA ATRA+As4S4 As4S4 / ATRA DA Induction Consolidation Maintenance (2 years) Xiao-jun Huang, Hong-hu Zhu, ASH 2012 AML session

  34. 北京大学人民医院 北京大学血液病研究所 Oral As4S4iv ATOp n=112 n=121 CR 98% 98% >0.05 Time to CR 30 days29 days>0.05 PML/RAR level CR 15.0% 2.1% <0.05 End consolidation 0 0 >0.05 Mol CR 100% 100% >0.05 Median Time to Mol CR 60 days60 days>0.05 Relapse 0.9% 0.8% >0.05 Xiao-jun Huang, Hong-hu Zhu, ASH 2012 AML session

  35. 北京大学人民医院 北京大学血液病研究所 Oral Realgar-Indigo naturalis formula yielded comparable high remission and long-term survival with ATO in newly diagnosed APL. Xiao-jun Huang, Hong-hu Zhu, ASH 2012 AML session

  36. Treatment of APL: view of guidelines 2. Recent studies for optimization - Role of arsenic as upfront treatment - ATRA+arsenic without chemotherapy - Oral formula of arsenic 3. Summary

  37. Arsenic as front-line treatment for newly-diagnosed APL *Dose: 0.16mg/kg/day D1-28; **Dose: 0.15mg/kg/day Monday through Friday of 4 weeks

  38. Future therapy for newly-diagnosed APL • arsenic + ATRA: mainstay of upfront treatment for newly-diagnosed APL • Oral arsenic: better tolerance and convenience • Chemotherapy: based on risk stratification

  39. Acknowledgements • Prof Zhen-yi Wang; Zhu Chen and Sai-juan Chen; Zhi-xiang Shen; Jun-min Li and colleagues at Shanghai Institute of Hematology, Department of Hematology, RuiJin Hospital

More Related